The histone demethylase KDM6B preserves adipogenic balance by restraining hypermetabolic LYVE1+ perivascular macrophages
White adipose tissue expandability protects against metabolic disease, yet the epigenetic programmes that maintain the macrophage states supporting this adaptation remain poorly defined. Here we show that the H3K27 demethylase KDM6B sustains LYVE1 + adipose tissue perivascular macrophages (PVMs) during diet-induced white adipose tissue expansion, thereby maintaining adipogenic balance. In humans, KDM6B expression in adipose tissue macrophages associates with insulin sensitivity, glycaemic control and reduced inflammation. In mice, myeloid Kdm6b deletion reprogrammes septal and capsular LYVE1 + macrophages towards a CLEC1A + hypermetabolic perivascular state, leading to defective adipogenesis, adipocyte hypertrophy, vascular rarefaction, inflammation and impaired glucose homeostasis. Mechanistically, KDM6B limits H3K27me3 deposition at the Bmp2 locus to maintain macrophage-derived BMP2 signalling to adipose progenitors. Myeloid Bmp2 deletion partially recapitulates Kdm6b -deficient adipose dysfunction, whereas recombinant BMP2 promotes homeostatic tissue remodelling. Collectively, KDM6B acts as an epigenetic switch controlling the metabolic fate of LYVE1 + PVMs, maintaining the balance between adipogenesis-supportive and metabolic PVM states that determine adipose tissue expandability and metabolic homeostasis.
Authors
- Wilfried Le Goff (ORCID: https://orcid.org/0000-0002-7611-9644)
- Amine Toubal (ORCID: https://orcid.org/0000-0001-7760-3852)
- Nicolas Venteclef (ORCID: https://orcid.org/0000-0002-6313-1214)
- Patricia Legoix
- B. Aznar (ORCID: https://orcid.org/0009-0006-4739-7000)
- Ivan Nemazanyy (ORCID: https://orcid.org/0000-0001-8080-839X)
- Wan Ting Kong (ORCID: https://orcid.org/0000-0002-9271-841X)
- Daniel Lindén (ORCID: https://orcid.org/0000-0003-4158-8018)
- Jean‐Baptiste Julla (ORCID: https://orcid.org/0000-0002-4497-5710)
- Gilberto Velho (ORCID: https://orcid.org/0000-0001-8811-363X)
- Florent Ginhoux (ORCID: https://orcid.org/0000-0002-2857-7755)
- Jean–François Gautier (ORCID: https://orcid.org/0000-0001-6458-2001)
- Marc Diedisheim (ORCID: https://orcid.org/0000-0002-0418-1107)
- Zaineb Mezdari (ORCID: https://orcid.org/0000-0002-2520-8559)
- Raphaëlle Ballaire
- Svetoslav Chakarov (ORCID: https://orcid.org/0000-0002-0665-5417)
- Eckardt Treuter (ORCID: https://orcid.org/0000-0002-4147-8989)
- Antoine Soprani
- Dina Chokr (ORCID: https://orcid.org/0000-0001-5797-7291)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Shanghai Jiao Tong University (CN)
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Karolinska Institutet (SE)
- Sorbonne Université (FR)
- Institut Necker Enfants Malades (FR)
- Centre de Recherche des Cordeliers (FR)
- Institut Cochin (FR)
- Unité de recherche sur les maladies cardiovasculaires et métaboliques (FR)
- Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR)
- Générale de Santé (FR)
- Structure fédérative de recherche Necker (FR)
- Shanghai Institute of Immunology (CN)
- Institut Curie (FR)
Publication Details
- Journal
- Nature Metabolism
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s42255-026-01639-0
- Citations
- 1
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.70
Funders
- Laboratoire d'Excellence Inflamex
- Fondation Francophone pour la Recherche sur le Diabète
- European Commission
- European Foundation for the Study of Diabetes
- Agence Nationale de la Recherche
- Cancerfonden
- Fondation pour la Recherche Médicale
- Karolinska Institutet
- Novo Nordisk
- Vetenskapsrådet
- Novo Nordisk Fonden
- National Institutes of Health
- Horizon 2020 Framework Programme
- Center for Innovative Medicine
- National Cancer Institute